Pfizer (PFE)
(Delayed Data from NYSE)
$28.18 USD
-0.09 (-0.32%)
Updated May 9, 2024 04:00 PM ET
After-Market: $28.12 -0.06 (-0.21%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Pfizer (PFE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$35.15 | $54.00 | $27.00 | 24.34% |
Price Target
Based on short-term price targets offered by 20 analysts, the average price target for Pfizer comes to $35.15. The forecasts range from a low of $27.00 to a high of $54.00. The average price target represents an increase of 24.34% from the last closing price of $28.27.
Analyst Price Targets (20)
Broker Rating
Pfizer currently has an average brokerage recommendation (ABR) of 2.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 22 brokerage firms. The current ABR compares to an ABR of 2.14 a month ago based on 22 recommendations.
Of the 22 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 40.91% and 4.55% of all recommendations. A month ago, Strong Buy made up 40.91%, while Buy represented 4.55%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 12 | 12 | 12 | 10 | 10 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.14 | 2.14 | 2.14 | 2.05 | 2.11 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/2/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
5/2/2024 | SVB Securities | David Risinger | Hold | Hold |
4/10/2024 | Berenberg Bank | Kerry Holford | Not Available | Hold |
4/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/22/2024 | Argus Research Corp. | David A Toung | Not Available | Hold |
3/1/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
2/23/2024 | Guggenheim Securities | Vamil Divan | Not Available | Strong Buy |
1/31/2024 | Daiwa America | Narumi Nakagiri | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.14 |
ABR (Last week) | 2.14 |
# of Recs in ABR | 22 |
Average Target Price | $35.15 |
LT Growth Rate | 9.90% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 152 of 252 |
Current Quarter EPS Est: | 0.44 |